Join Now

Member Blog: Quality Over Quantity – Why Stronger is Not Always Better

by Andrew Kaye, Sweet Leaf Madison Capital

Over the last 15 years, cannabis has seemingly catapulted away from the days of schwag and dirt weed. Today, we are seeing THC levels well beyond percentages that were displayed in dispensaries 10 years ago when cannabis first became legal in certain states. Advancements in technology, a better understanding of growing cannabis, and strain cloning has allowed for growers and chemists alike to fine-tune the plant to offer more bang for our buck – but not everyone needs to blast off every time they light up, right? 

Right. 

Recently, there has been a shift in the way we approach cannabis use, especially for medicinal purposes – proper dosing is everything. These stronger strains that have been Frankensteined together to ensure a potent one-hit high making it nearly impossible to provide a controlled dose for someone just looking for a chill evening or relief from their chronic pain. Granted, these strains have their place among seasoned tokers, but for others who are novice cannabis enthusiasts or patients looking for a treatment, stronger does not necessarily mean better. More intention should be put toward partaking, and it is as simple as asking yourself a few questions: How do I want to feel? What do I want to do? Where am I going? What hurts? Who is part of the experience?

Realistically, when was the last time you went to the bar to enjoy a casual night out with friends and started throwing back tequila shots until your knees buckled? 

Hopefully, you are not recounting a night where that happened, but if so, you can probably guarantee that you would not put yourself in that situation again, at least not right away. Be honest with yourself, answer the questions above and chat with budtenders to find the best solution for you. 

Knowledge is Your Best Friend

For a lot of people entering dispensaries for the first time, they see these high THC numbers and equate it to a better high, but the reality is that cannabis potency can be attributed to more than the THC percentage. Terpenes, differing cannabinoids and other compounds found within the plant also play a major role in how strong the strain is and what effect it has on your body and mind. Think of the subtlety of wine versus the kick of jello shots.

This is why it is important to talk with budtenders to better understand which strain is going to work best for what you are seeking. The problem today is that dispensaries are experiencing high turnover rates, as 55% of budtenders who held jobs over the last year left within 12 months of starting, according to a Headset market report. Losing seasoned employees not only impacts the store itself, but customer service tends to take a hit (no, not that type of hit). Inexperienced budtenders might be rushed to the counter without proper training, leading to misguided direction and customers walking away with flower or edibles that will send them to space, or to a space that they did not intend to go. Again, there is nothing wrong with having highly potent strains, but making and distributing them comes with a responsibility toward customer and patient care. As more states migrate to adult use cannabis, many are abandoning the medical dispensary model and focusing on high-profit strains, not curative or palliative care.  Dispensaries need to ensure they are properly onboarding and training new employees to provide the best service possible. 

The Future of Cannabis

As science improves and technology becomes more refined, cannabis potency is going to continue to go up, but it also means that mid- and low-potency strains will get better. If you look at the craft beer industry, the days of high abv IPAs and stouts are slowly fading and more focus is being put on taste and balance. 

Since 2014, there has been an almost “gold rush” mentality where growers were fine-tuning their product at a high rate to offer a better punch than their competitors, but in 2023, after nearly 10 years of legal cannabis, customers are looking to refine their tastes and highs. 

For most, the quality of the strain is going to be far more beneficial than the quantity of THC, but at the end of the day it is all preference. So do yourself a favor the next time your supply is low and chat with budtenders – lean on their expertise and compare with your own research. Try different strains along the potency spectrum and really consider taste. No one consumer is the same; make your experience yours. The higher the price is not always the nicer the nice.


Andrew Kaye has been involved in all aspects of the financial services industry, as a fund portfolio investment manager, investment banker, family office investor and attorney.  He has worked with start-ups on their first raise through global enterprises undertaking billion-dollar stock offerings, and has significant investment experience in the cannabis industry. Currently, Andrew works as Sweet Leaf Madison Capital’s Chief Commercial Officer. Lending his expertise toward the creation of middle market financing solutions for real estate and equipment financing needs in the cannabis space.”

“Sweet Leaf Madison Capital provides non-dilutive, asset-based lending solutions to the underserved middle market of the cannabis industry by originating real estate loans, equipment financing, securitized term loans, and more for entrepreneurs and businesses. The company is based in Denver, Colorado and has offices in New York City and West Palm Beach, Florida. To learn more or complete a loan application, visit Sweet Leaf Madison Capital online, or continue the conversation on LinkedInTwitter and Facebook.”

Andrew J. Kaye is Chief Commercial Officer of Sweet Leaf Madison Capital. He can be reached at akaye@sweetleafmadison.com.

Member Blog: Wine is the Mentor Cannabis Needs – How The Industry Can Mimic Vino to Find Global Success

by Andrew Kaye, Sweet Leaf Madison Capital

Picking up an eighth of Blue Dream right next to where you buy a bottle of merlot used to mean meeting your dealer in the parking lot behind the liquor store, but now it’s as simple as going to the shop next door. The widespread legalization of recreational cannabis over the last 10 years in the United States and abroad has led to a rollercoaster ride of gains and losses for the industry, but the future is still looking as green as ever. Nevertheless, there’s still a lot to learn, specifically from other industries like wine, who continue to rake in billions of dollars each year. 

Given that wine has a few thousand years on cannabis as a commodity, cannabis has an opportunity to make up for lost time over the next decade. Due in part to more countries either loosening laws and restrictions or legalizing cannabis all together, the global market will start to see significant growth as international demand increases. In the years to come, cannabis companies will not only have opportunities to expand notoriety and increase demand, but regional terroirs could hold the same esteem as wine-lovers’ favor bottles from Burgundy or Tuscany. 

New Players, Same Game

Nearly 30 countries have either decriminalized possession or made cannabis medically legal, with others like Canada, Uruguay, and Malta legalizing recreational cannabis. Germany and Luxembourg are also following suit

Each change leads to a new open market, with new economic opportunities. If we take a look at how the wine industry evolved from 1990 to present day, countries like Bulgaria, Germany, Portugal and Moldova were amongst the top 10 exporters in the world, behind the big three, Italy, France, and Spain. But where there is growth, there is contraction, and in those 30 years, contenders such as Australia, New Zealand and Chile have seen massive growth and recognition for their wines and are now able to go head-to-head with the big three, while Bulgaria and Moldova do not crack the top ten today.

The same is true for cannabis. As Germany moves toward legalization, which is predicted for 2024, it must figure out how to create supply for the country’s increasing demand. For years the Germans have been importing Canadian cannabis for medical use, accounting for 38% of its cannabis imports since 2017 – bringing in nearly 12 tons of flower and extracts in the first six months of 2022 alone. So what is good news to a potentially burgeoning European market, is good news for Canada – at least for the time being. The most recent proposal out of Berlin seems to exclude imports in the future and instead lays out plans to cultivate and distribute all within its own borders. Therefore, companies like Aurora Cannabis have just under two years to get the most out of their relationship before it is time to split up and move on. 

On the other hand, we see companies seizing opportunities to expand into the global market. For example, Cookies, a California-based cannabis retailer and product brand, has recently opened a recreational dispensary in Bangkok, Thailand. This is just months after the country moved to legalize cannabis and establishes Cookies’ fourth international store – they also have three medicinal locations in Israel. 

Endless Possibilities

This is only the beginning. Global legal cannabis is still in its early days, and diversification of the market is going to be the future. We are going to start seeing countries promote both domestic consumption alongside international export to take advantage of opportunities abroad, while, much like wine, region-specific strains could become popular as cloning, hybridization and other advancements are finding their way into growing operations. Ultimately, specialized strains will become a cherished commodity amongst global cannabis aficionados. Boosting cannabis tourism, much like what we see in Amsterdam or Humboldt County, across the world. 

As the industry grows, it will be important for businesses and brands to pull inspiration from those who paved the way, and wine seems to be the best place to start. Learning how to boost recognition to increase global demand will be essential, and big corporations will find this easier than small businesses, but that does not mean growth opportunities will dry up for those small players. Specialization and quality products will shine in a global market as well. 

So, drink up, light up, and renew your passport. Cannabis, like wine, is circling the globe!


Andrew Kaye has been involved in all aspects of the financial services industry, as a fund portfolio investment manager, investment banker, family office investor and attorney.  He has worked with start-ups on their first raise through global enterprises undertaking billion-dollar stock offerings, and has significant investment experience in the cannabis industry. Currently, Andrew works as Sweet Leaf Madison Capital’s Chief Commercial Officer. Lending his expertise toward the creation of middle market financing solutions for real estate and equipment financing needs in the cannabis space.”

“Sweet Leaf Madison Capital provides non-dilutive, asset-based lending solutions to the underserved middle market of the cannabis industry by originating real estate loans, equipment financing, securitized term loans, and more for entrepreneurs and businesses. The company is based in Denver, Colorado and has offices in New York City and West Palm Beach, Florida. To learn more or complete a loan application, visit Sweet Leaf Madison Capital online, or continue the conversation on LinkedInTwitter and Facebook.”

Andrew J. Kaye is Chief Commercial Officer of Sweet Leaf Madison Capital. He can be reached at akaye@sweetleafmadison.com.

 

Member Blog: What Ever Happened with the New York Minute in the Cannabis Industry?

by Andrew Kaye, Sweet Leaf Madison Capital 

2023 is New York’s year for cannabis – at least that is what we are being told. It has nearly been two years since the state voted in legalized recreational use and sale, but the state has been very slow in getting processing facilities and dispensaries up and running, with only three of the 66 licensed establishments in operation as of the end of February. It is no secret that New York has the potential to be one of the largest cannabis markets in the world. This year alone, New York City is expecting over 50 million visitors – many of them looking to buy legal weed. 

Everyone can see the value that New York will bring to the industry, but why does it feel like they are dragging their feet to bring something to the table? 

It appears that the state may have bit off more than it can chew. 

A lack of understanding of the complexities of securing commercial cannabis real estate combined with the fact that raising necessary capital has been slow-moving, has made it so that cultivators now have too much supply with no means of distribution to meet the demand. 

Good intentions, slow follow-through 

The guiding social equity program behind New York’s retail licensing system is a giant leap forward within the cannabis industry to bring up those directly affected by the failed war on drugs. The Cannabis Adult-Use Retail Dispensary (CAURD) licenses are aimed at prioritizing these underserved communities and awarding licenses to those who have been convicted of marijuana-related crimes, or have a direct family member that has been charged, with the opportunity to open retail locations. Nonprofits that work directly with these communities have a chance at obtaining licenses as well. 

One of the most enticing things about these licenses is that the Dormitory Authority of the State of New York (DASNY) has been tasked with finding storefronts for entrepreneurs who have been granted licenses and even build them out for them. To do so, the state has contracted 10 firms to design and construct each dispensary. But again, the state has been very slow in getting dispensaries up and running. It seems that DASNY has discovered the reality that finding landlords willing to lease to a cannabis business may be more daunting than expected. 

This only adds to the sense of urgency that has lingered in the air for the last two years. Businesses are ready to get up and running just to play catch up to the underground market that is thriving across New York City’s boroughs. Currently, New York has estimated that there are roughly 1,400 unlicensed retailers operating in the city. Unregulated sales mean that weed has the potential of going to underage kids, being tainted and it is all ultimately going untaxed. New Yorkers and the state are hurting due to the delayed rollout, but there is still time to change things around.

Since spaces are limited for license holders waiting on DASNY to figure out the real estate landscape, the state has started to give licensees the option to go out on their own to secure a location for the sake of being one of the first to the legal market. 

The problem is that this good news comes with a caveat. If a licensee decides to break out on their own, they will be forgoing their share of the $200 million public-private fund that DASNY has budgeted to help with operating costs. This fund is essentially a state loan that each retailer will have to pay back, including interest. But the problem is that DASNY has not yet raised the necessary funds to dole out to retailers – the only amount that the public is aware of is the $50 million that the state provided. 

So, the million dollar questions are, do these entrepreneurs take a chance to be first to the scene? Or do they trust that the money and real estate issues will work themselves out? 

It is hard to say. But what we do know is that there are new cultivating and processing licenses being secured this year as well, and a huge backlog of weed in storage, so there will be no lack of product once the doors to the public open up – right now, it is just a matter of time. 

So maybe NYC should get out of its own way, put a bit more “market” in the cannabis market, and let 1,000 blossoms bloom! 


Andrew Kaye has been involved in all aspects of the financial services industry, as a fund portfolio investment manager, investment banker, family office investor and attorney.  He has worked with start-ups on their first raise through global enterprises undertaking billion-dollar stock offerings, and has significant investment experience in the cannabis industry. Currently, Andrew works as Sweet Leaf Madison Capital’s Chief Commercial Officer. Lending his expertise toward the creation of middle market financing solutions for real estate and equipment financing needs in the cannabis space.”

“Sweet Leaf Madison Capital provides non-dilutive, asset-based lending solutions to the underserved middle market of the cannabis industry by originating real estate loans, equipment financing, securitized term loans, and more for entrepreneurs and businesses. The company is based in Denver, Colorado and has offices in New York City and West Palm Beach, Florida. To learn more or complete a loan application, visit Sweet Leaf Madison Capital online, or continue the conversation on LinkedIn, Twitter and Facebook.”

 

Andrew J. Kaye is Chief Commercial Officer of Sweet Leaf Madison Capital. He can be reached at akaye@sweetleafmadison.com.

This site uses cookies. By using this site or closing this notice, you agree to the use of cookies and our privacy policy.